Clinical trial
Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's…
NCT00244322 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00244322 |
|---|---|
| Title | Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease |
| Official title | LY450139: Tolerability and Biomarker Assessment in Subjects With Mild to Moderate Alzheimer's Disease |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | LY450139 dihydrate, placebo |
| Enrollment | 45 |
| Start date | Oct 1, 2005 |
| Completion | Dec 1, 2006 |
| First posted | Oct 26, 2005 |
| Last update posted | May 28, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: